News & Updates
Filter by Specialty:
ALESIA: Long-term data support first-line alectinib in Asians with ALK-positive NSCLC
First-line treatment with alectinib appears to produce sustained clinical benefit in Asian patients with advanced, ALK-positive nonsmall cell lung cancer (NSCLC) through 5 years of follow-up, according to long-term data from the phase III ALESIA presented at the ESMO Asia Congress 2022.
ALESIA: Long-term data support first-line alectinib in Asians with ALK-positive NSCLC
09 Dec 2022
Novel MET kinase inhibitor counteracts TKI resistance in NSCLC
Treatment with SCC244, a novel small molecule inhibitor of the enzyme MET kinase, appears to help overcome the resistance to tyrosine kinase inhibitors (TKI) mediated by MET amplification in nonsmall cell lung cancer (NSCLC), reports a new study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).
Novel MET kinase inhibitor counteracts TKI resistance in NSCLC
09 Dec 2022
Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC
The addition of radiation therapy to chemotherapy may be more detrimental than beneficial in patients with resectable stage III nonsmall‐cell lung cancer (NSCLC), being associated with a heightened risk of severe cardiac events, as shown in a study.
Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC
09 Dec 2022
Progestin shows therapeutic potential in PR-positive endometrial cancer
Progestin therapy appears to yield high response rates in advanced stage and recurrent endometrial cancer that is positive for progesterone receptor (PR) expression, while having low toxicity, according to a study.
